Proteomic Dissection of DEV VP26: Linking Cytoskeleton Dynamics to Viral Proliferation

Study Background and Research Question

Duck viral enteritis (DVE), caused by the duck enteritis virus (DEV), remains a significant threat to waterfowl, leading to severe morbidity and mortality in affected populations. Despite its impact, the molecular interactions between DEV and host cellular machinery have been poorly characterized. The present study by Chen et al. sought to elucidate which host proteins interact with the DEV capsid protein VP26 and how these interactions influence viral proliferation, with a particular focus on cytoskeletal networks (Chen et al., 2025).

Key Innovation from the Reference Study

A central innovation of this work lies in its systematic mapping of the VP26 interactome within infected host cells. Using a recombinant DEV expressing an epitope-tagged VP26, the authors identified 17 host proteins that physically interact with VP26, the majority of which are cytoskeletal or actin-binding proteins. Critically, the study demonstrates that the host actin–myosin II network, and specifically MYH9 (non-muscle myosin IIA heavy chain), is pivotal for DEV proliferation. By directly linking viral replication efficiency to the integrity of the host cytoskeleton, the research advances our understanding of herpesvirus–host interactions at the molecular level (Chen et al., 2025).

Methods and Experimental Design Insights

To uncover the VP26 interactome, the authors engineered a recombinant DEV strain expressing VP26 fused to a FLAG tag (rVP26-Flag), enabling affinity purification of VP26-associated complexes from infected chicken embryo fibroblasts. Co-immunoprecipitation (Co-IP) was followed by liquid chromatography–tandem mass spectrometry (LC–MS/MS) for unbiased identification of host binding partners. Functional annotation of the 17 candidate interactors emphasized cytoskeletal roles, including microfilament binding, actin–myosin motor activity, and actin filament modulation. To test the functional relevance of these interactions, chemical inhibitors and gene knockdown approaches were employed:

• Actin polymerization was disrupted using cytochalasin D and Latrunculin A, both established reversible inhibitors of actin assembly.
• MYH9 expression was reduced via siRNA-mediated knockdown.
• Myosin II ATPase activity was inhibited using (-)-Blebbistatin, a selective myosin II inhibitor.

Viral titers were quantified post-treatment to assess the impact of cytoskeletal disruption on DEV proliferation.

Protocol Parameters

• cell model | chicken embryo fibroblast | DEV–host interaction studies | Established, permissive host cell type for DEV infection | paper
• actin polymerization inhibitor (Latrunculin A) | 1–10 μM, 10 min to overnight | cytoskeleton disaggregation, viral titration | Rapid and reversible inhibition of actin assembly, recapitulating cytoskeleton disruption | product_spec
• myosin II ATPase inhibitor (Blebbistatin) | 50 μM, in vitro; 2 mg/kg, in vivo | DEV infection suppression | Targeted inhibition of myosin II motor function to probe cytoskeletal dependency | paper
• siRNA knockdown (MYH9) | sequence-specific, 48 h | host factor validation | Directly tests MYH9’s role in viral proliferation | paper
• viral titer assay | TCID50 or plaque assay | quantification of DEV replication | Standard endpoint for virological impact | paper

Core Findings and Why They Matter

The proteomic screen highlighted a cluster of cytoskeletal proteins as prime interactors of VP26, including MYH9, MYH10, MYO5A, TMOD3, and Xirp1. Functional validation showed that:

• Disruption of actin polymerization using Latrunculin A or cytochalasin D significantly reduced DEV titers, demonstrating the necessity of an intact actin cytoskeleton for efficient viral replication (Chen et al., 2025).
• Knockdown of MYH9 via siRNA markedly decreased viral proliferation, implicating this non-muscle myosin II isoform as a crucial host factor (Chen et al., 2025).
• Blebbistatin-mediated inhibition of myosin II ATPase activity profoundly suppressed DEV infection both in vitro and in vivo, confirming the functional importance of cytoskeletal motor activity for the viral lifecycle.

Mechanistically, these results align with the hypothesis that DEV VP26 exploits the host’s actin–myosin II machinery for processes such as intracellular trafficking, capsid transport, and potentially nuclear entry, which are fundamental to the herpesvirus replication cycle.

Comparison with Existing Internal Articles

Internal literature consistently describes Latrunculin A as a potent, reversible inhibitor of actin assembly with proven utility for disrupting the actin cytoskeleton in both tumor and non-tumor cell models (internal, internal). These articles emphasize Latrunculin A’s rapid action and reversibility, facilitating reproducible investigation of cell morphology, motility, and viral pathogenesis. The present DEV study directly extends these principles, providing primary data that actin cytoskeleton disruption via Latrunculin A impairs viral proliferation, thus offering a practical protocol for dissecting cytoskeleton–virus interactions. One internal review (internal) highlights emerging applications of Latrunculin A in viral pathogenesis, which the current study substantiates with new evidence of its efficacy in a herpesvirus model. Collectively, the reference and internal resources converge on the importance of reversible actin assembly inhibition for advanced cellular and virological research.

Limitations and Transferability

While the study’s proteomic identification and functional assays provide compelling evidence for the actin–myosin II network’s role in DEV proliferation, several limitations warrant consideration:

• Host–pathogen interactions were characterized primarily in chicken embryo fibroblast cells, which may not fully recapitulate in vivo tissue complexity or responses in natural waterfowl hosts (Chen et al., 2025).
• Although chemical inhibitors like Latrunculin A and Blebbistatin are highly specific, off-target or compensatory effects cannot be entirely excluded and require corroboration with genetic approaches.
• Transferability to other herpesviruses or non-avian systems should be inferred with caution, pending direct experimental validation.

Why this cross-domain matters, maturity, and limitations

The actin–myosin II cytoskeleton is a universal component of eukaryotic cells, and its exploitation by viruses is a recurrent theme across virology. The DEV VP26 findings underscore the broader relevance of cytoskeletal dynamics in host–pathogen interactions, bridging cell biology and infectious disease research. However, the maturity of this cross-domain insight is currently strongest within the context of alphaherpesviruses and avian models; application to other viral systems should be approached as a research hypothesis rather than a generalizable protocol (Chen et al., 2025).

Research Support Resources

Researchers aiming to reproduce or extend these findings can leverage specialized reagents to investigate actin cytoskeleton disruption and viral–host interactions in vitro. Latrunculin A (SKU B7555) from APExBIO is a well-characterized, reversible inhibitor of actin assembly, validated for rapid and reproducible cytoskeleton disaggregation in a range of cellular systems (product_spec). Its application, as demonstrated in the reference study, enables precise interrogation of actin-dependent processes during viral infection and cell biology workflows. For protocol specifics and optimization, consult both the reference publication and the product’s technical documentation.